Phase 3 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with locally advanced cervical cancer at a specific stage (FIGO 2018 stages IB3, IIA2, or IIB with a tumour larger than 4 cm), confirmed by two qualified doctors using physical examination and imaging.
• People who have at least one tumour that can be measured on scans, particularly MRI, at the start of the trial.
• People whose cervical cancer has been confirmed by tissue testing as one of these types: squamous cell carcinoma, adenocarcinoma (common type), or adenosquamous carcinoma.
• People whose tumour tests positive for a protein called PD-L1, with a Combined Positive Score (CPS) of 1 or higher (confirm with trial site).
• People aged 18 to 70 years old.
• People who are generally well enough to carry out daily activities with little or no limitation, based on a standard health performance scale called ECOG (score of 0 or 1).
• People whose blood test results fall within acceptable ranges, showing healthy levels of white blood cells, platelets, liver function, and kidney function, as assessed by the trial team.
• People who are willing and able to attend follow-up appointments and follow the trial requirements.
• People who are willing to sign a consent form agreeing to the trial's conditions.
• People who agree to use effective contraception during the trial and for at least 5 months after the last dose of the immunotherapy drug, or 6 months after chemotherapy ends — whichever period is longer.

Who may not be able to join:

• People who currently have, or have a history of, an active autoimmune disease that has required treatment — such as autoimmune liver disease, lung inflammation, eye inflammation, bowel inflammation, thyroid problems, or asthma requiring certain medications, among others.
• People who have previously been treated with immune checkpoint inhibitor drugs (such as anti-PD-1 or anti-PD-L1 medicines), or who are known to have an allergy to any component of the study drugs or similar medicines.
• People with a known HIV infection, active hepatitis B, or active hepatitis C.
• People who have taken immune-suppressing medications, including steroid medicines above a certain dose, within the 2 weeks before starting the trial.
• People who have been diagnosed with another cancer (other than cervical cancer) within the past 5 years.
• People who have taken part in another clinical drug trial or received an experimental treatment within the 4 weeks before joining (observational studies without treatment are generally allowed).
• People who are pregnant or currently breastfeeding.
• People with serious uncontrolled health conditions, including certain heart problems, a heart attack within the past 6 months, uncontrolled high blood pressure, a stroke or brain condition within the past 6 months, serious blood clotting or bleeding disorders, significant kidney or liver abnormalities, or an active infection requiring treatment within 14 days before starting the trial.
• People who have received a live or weakened (attenuated) vaccine within the 4 weeks before starting the trial (standard inactivated flu vaccines are generally permitted).
• People who have previously had a bone marrow transplant or a solid organ transplant from a donor.
• People with a current problem with drug or alcohol misuse.
• People who the trial doctors believe are unlikely to be able to follow the trial's procedures and requirements.

Important: Always verify eligibility with the trial site directly before applying.